A Phase 2, Open-label, Single Arm, Exploratory, Observational Study to Evaluate the Safety and Tolerability of PBI-4050 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Trial Profile

A Phase 2, Open-label, Single Arm, Exploratory, Observational Study to Evaluate the Safety and Tolerability of PBI-4050 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Completed
Phase of Trial: Phase II

Latest Information Update: 23 May 2018

At a glance

  • Drugs PBI 4050 (Primary) ; Nintedanib; Pirfenidone
  • Indications Idiopathic pulmonary fibrosis
  • Focus Adverse reactions
  • Sponsors ProMetic Biosciences
  • Most Recent Events

    • 23 May 2018 Results assessing the effect of PBI-4050 alone or in combination with pirfenidone or nintedanib on blood biomarkers linked to the fibrotic process presented at the 114th International Conference of the American Thoracic Society.
    • 22 May 2018 Results assessing the effect of PBI-4050 alone or in combination with pirfenidone or nintedanib on blood biomarkers linked to the fibrotic process, published in a ProMetic Life Sciences media release.
    • 24 May 2017 Results presented at the 113th International Conference of the American Thoracic Society
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top